BRIEF-Revive Therapeutics announces U.S. FDA acceptance of IND of Bucillamine for treatment of cystinuria

Wed Jul 6, 2016 9:26am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 6 (Reuters) - Revive Therapeutics Ltd

* Revive therapeutics Ltd. announces U.S. FDA acceptance of IND of Bucillamine for treatment of cystinuria Source text for Eikon: Further company coverage: )